PI3K-IN-38

CAS No. 1382979-64-7

PI3K-IN-38( —— )

Catalog No. M35576 CAS No. 1382979-64-7

PI3K-IN-38 is an orally available and potent PI3K inhibitor with an IC50 value of 0.541 μM for PI3K-α. PI3K-IN-38 exhibits anticancer and anti-inflammatory activity and inhibits tumor growth in vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 172 In Stock
10MG 254 In Stock
25MG 392 In Stock
50MG 531 In Stock
100MG 710 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PI3K-IN-38
  • Note
    Research use only, not for human use.
  • Brief Description
    PI3K-IN-38 is an orally available and potent PI3K inhibitor with an IC50 value of 0.541 μM for PI3K-α. PI3K-IN-38 exhibits anticancer and anti-inflammatory activity and inhibits tumor growth in vivo.
  • Description
    PI3K-IN-38 (compound 123) is an orally active PI3K inhibitor with IC50 of 0.541 μM (PI3K-α). PI3K-IN-38 shows activities of anticancer and anti-inflammatory, which inhibis tumor growth in vivo.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1382979-64-7
  • Formula Weight
    380.44
  • Molecular Formula
    C20H24N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1(C)C2=NC=3C(N2CCO1)=NC(=NC3N4CCOCC4)C5=CC=C(N)C=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Dotson J, et al. Tricyclic pi3k inhibitor compounds and methods of use. WO2012082997A1.
molnova catalog
related products
  • IC-87114

    A potent and selective PI3Kδ inhibitor with IC50 of 0.5 uM.

  • mTOR inhibitor 9d

    mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia, skin cancer, breast cancer, lung cancer and colon cancer.

  • NIBR-17

    NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.